Delcath Systems Q2 revenue rises, beats estimates
DCTH•Analyst coverage
The current average analyst rating on the shares is buy, with 6 strong buy or buy recommendations, no hold ratings and no sell or strong sell ratings.
The average consensus recommendation for the medical equipment, supplies & distribution peer group is buy.
Wall Street's median 12-month price target for Delcath Systems Inc is $21.50, about 70.2% above its August 5 closing price of $12.63.
Drivers of the quarter
- HEPZATO volume growth — The company reported approximately 30% growth in HEPZATO volume in Q2 2026 vs. Q2 2025.
- Treatment center expansion — Delcath said growth in its active treatment center network and physician adoption drove increased HEPZATO usage.
- Clinical trial activity — The company attributed higher R&D expenses to increased clinical headcount and clinical trial activity.
